245 related articles for article (PubMed ID: 34032171)
1. Influence of Social and Cultural Factors on the Decision to Consent for Monoclonal Antibody Treatment among High-Risk Patients with Mild-Moderate COVID-19.
Bierle DM; Ganesh R; Wilker CG; Hanson SN; Moehnke DE; Jackson TA; Ramar P; Rosedahl JK; Philpot LM; Razonable RR
J Prim Care Community Health; 2021; 12():21501327211019282. PubMed ID: 34032171
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate COVID-19 at high risk for disease progression: a prospective cohort study.
Savoldi A; Morra M; De Nardo P; Cattelan AM; Mirandola M; Manfrin V; Scotton P; Giordani MT; Brollo L; Panese S; Lanzafame M; Scroccaro G; Berkell M; Lippi G; Konnova A; Smet M; Malhotra-Kumar S; Kumar-Singh S; Tacconelli E;
Eur J Clin Microbiol Infect Dis; 2022 Jul; 41(7):1065-1076. PubMed ID: 35727429
[TBL] [Abstract][Full Text] [Related]
3. Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019.
Ganesh R; Philpot LM; Bierle DM; Anderson RJ; Arndt LL; Arndt RF; Culbertson TL; Destro Borgen MJ; Hanson SN; Kennedy BD; Kottke BB; Larsen JJ; Ramar P; Rosedahl JK; Seville MT; Speicher LL; Tulledge-Scheitel SM; Wilker CG; Razonable RR
J Infect Dis; 2021 Oct; 224(8):1278-1286. PubMed ID: 34279629
[TBL] [Abstract][Full Text] [Related]
4. A Comparison of SARS-COV-2 Neutralizing Antibody Therapies in High-Risk Patients with Mild to Moderate COVID-19 Disease at a Single Academic Hospital.
Farcy DA; Dalley MT; Miro G; Swalley P; Sherman D; Nash J; Jodoin K; Cubeddu LX; Zitek T; Goldszer R
J Emerg Med; 2022 Jan; 62(1):83-91. PubMed ID: 34489146
[TBL] [Abstract][Full Text] [Related]
5. Impact of COVID vaccine and comorbidities in patients receiving casirivimab-imdevimab monoclonal antibody during SARS-CoV-2 B.1.617.2 (Delta) surge: A real-world study.
Agrawal P; Damania D; Cseh A; Grab J; Strom L; Frank B; Patel D; Clyatt G
Vaccine; 2023 Aug; 41(35):5195-5200. PubMed ID: 37451874
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 neutralizing antibody therapies: an early retrospective cohort study of 26 hospitalized patients treated with bamlanivimab or casirivimab/imdevimab.
Heller M; Henrici C; Büttner J; Leube S; Treske I; Pospischil P; Doll M; Schanz I; Hallier A; Herrmann E; Schmidt M; Sarrazin C
Int J Infect Dis; 2023 Apr; 129():260-265. PubMed ID: 36690138
[TBL] [Abstract][Full Text] [Related]
7. Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge.
Bierle DM; Ganesh R; Razonable RR
J Clin Virol; 2021 Dec; 145():105026. PubMed ID: 34775142
[TBL] [Abstract][Full Text] [Related]
8. Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19.
McCreary EK; Bariola JR; Wadas RJ; Shovel JA; Wisniewski MK; Adam M; Albin D; Minnier T; Schmidhofer M; Meyers R; Marroquin OC; Collins K; Garrard W; Berry LR; Berry S; Crawford AM; McGlothlin A; Linstrum K; Nakayama A; Montgomery SK; Snyder GM; Yealy DM; Angus DC; Kip PL; Seymour CW; Huang DT; Kip KE
JAMA Netw Open; 2022 Apr; 5(4):e226920. PubMed ID: 35412625
[TBL] [Abstract][Full Text] [Related]
9. Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany.
Koehler J; Ritzer B; Weidlich S; Gebhardt F; Kirchhoff C; Gempt J; Querbach C; Hoffmann D; Haller B; Schmid RM; Schneider J; Spinner CD; Iakoubov R
Infection; 2021 Dec; 49(6):1313-1318. PubMed ID: 34244967
[TBL] [Abstract][Full Text] [Related]
10. Single Site Experience of the use of Monoclonal Antibodies for the Treatment of COVID-19 in High-risk Pediatric and Young Adult Patients.
Bahakel H; Murphy C; Frenck RW; Grimley MS; Marsh RA; Paulsen GC; Haslam DB; Phillips CL; Courter J; Spearman P; Schulert G; Danziger-Isakov L
Pediatr Infect Dis J; 2022 Dec; 41(12):985-988. PubMed ID: 36219876
[TBL] [Abstract][Full Text] [Related]
11. A Propensity-Matched Cohort Assessing Impact of a Neutralizing Monoclonal Antibody in Mild-to-Moderate Coronavirus Disease 2019.
Abbas M; Farhat N; Hammoud Z; Dickey C; Shuayto A; Chen NW; Hsaiky LM; Sims M; Sengstock D; Schramski J; Shamoon Z
J Intensive Care Med; 2023 Jun; 38(6):511-518. PubMed ID: 36775970
[No Abstract] [Full Text] [Related]
12. Real-World Experience of Bamlanivimab for Coronavirus Disease 2019 (COVID-19): A Case-Control Study.
Kumar RN; Wu EL; Stosor V; Moore WJ; Achenbach C; Ison MG; Angarone MP
Clin Infect Dis; 2022 Jan; 74(1):24-31. PubMed ID: 33846730
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Treatment of Hematological Patients with SARS-CoV-2 Infection Including Anti-SARS-CoV-2 Monoclonal Antibodies: A Single-Center Experience Case Series.
Boeckel GR; Hölscher SD; Bürger C; Jacob T; Krekeler C; Shumilov E; Reicherts C; Bleckmann A; Lenz G; Vollenberg R; Tepasse PR
Curr Oncol; 2022 Mar; 29(4):2312-2325. PubMed ID: 35448162
[TBL] [Abstract][Full Text] [Related]
14. Disparities in COVID-19 Monoclonal Antibody Delivery: a Retrospective Cohort Study.
Wu EL; Kumar RN; Moore WJ; Hall GT; Vysniauskaite I; Kim KA; Angarone MP; Stosor V; Ison MG; Bba AF; Achenbach CJ; Gates KL
J Gen Intern Med; 2022 Aug; 37(10):2505-2513. PubMed ID: 35469360
[TBL] [Abstract][Full Text] [Related]
15. Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019.
O'Horo J; Challener DW; Anderson RJ; Arndt RF; Ausman SE; Hall ST; Heyliger A; Kennedy BD; Sweeten PW; Ganesh R; Razonable RR
Mayo Clin Proc; 2022 May; 97(5):943-950. PubMed ID: 35512884
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of neutralizing monoclonal antibodies in transplant recipients with mild-to-moderate COVID-19.
Arimura K; Tagaya E; Kikuchi K; Mitsuda T; Ebihara F; Maruyama T; Hamada Y; Unagami K; Kanzawa T; Sekiguchi H; Shimamoto K; Ishida H; Egawa H; Tanaka J; Kawana M
Transpl Immunol; 2023 Apr; 77():101777. PubMed ID: 36584927
[TBL] [Abstract][Full Text] [Related]
17. Investigating demographic differences in patients' decisions to consent to COVID-19 research.
Robertson K; Reimold K; Moormann AM; Binder R; Matteson KA; Leftwich HK
J Matern Fetal Neonatal Med; 2023 Dec; 36(1):2148097. PubMed ID: 36597819
[TBL] [Abstract][Full Text] [Related]
18. Effect of monoclonal antibody therapy on the endogenous SARS-CoV-2 antibody response.
Kim PS; Dimcheff DE; Siler A; Schildhouse RJ; Chensue SW
Clin Immunol; 2022 Mar; 236():108959. PubMed ID: 35218964
[TBL] [Abstract][Full Text] [Related]
19. Real-world evaluation of the impact of two anti-SARS-CoV-2 monoclonal antibody regimens on COVID-19 hospitalizations in older adults.
Sobolewski KA; Smoke SM; Brophy A; Vassallo AV; Chen B; Hilden P; Patterson R; Pittiglio M; Raja K; Handler E; Freer C
J Med Virol; 2022 Jun; 94(6):2493-2499. PubMed ID: 35199356
[TBL] [Abstract][Full Text] [Related]
20. Real-world Assessment of 2879 COVID-19 Patients Treated With Monoclonal Antibody Therapy: A Propensity Score-Matched Cohort Study.
Cooper MH; Christensen PA; Salazar E; Perez KK; Graviss EA; Nguyen D; Musser JM; Huang HJ; Liebl MG
Open Forum Infect Dis; 2021 Nov; 8(11):ofab512. PubMed ID: 35559124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
